Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
MPN updates from iwMDS-iwMPN 2024
2nd International Workshop on MDS & MPNs
28–30 June 2024 | Boston, MA
Expert-led presentations & roundtable discussions on myeloproliferative neoplasms from iwMDS/iwMPN 2024.
iwMDS/iwMPN 2024 was supported by BMS, AbbVie, Astex Pharmaceuticals, Geron, Keros Therpaeutics, Sobi, Menarini-Stemline, Syros, Agios and GSK. Supporters have no influence over the production of the content.
Biology of MPNs
Calreticulin biology and targeting
Bethan Psaila University of Oxford, Oxford, United Kingdom
Pathophysiology of progression
Ronald Hoffman Icahn School of Medicine at Mount Sinai, New York City, NY, United States
CHIP, JAK2 and MPN
David Steensma Ajax Therapeutics, Cambridge, MA, United States
PV and ET
New options for the management of ET
Kristen Pettit University of Michigan, Ann Arbor, MI, United States
Current data regarding young MPN patients
Lucia Masarova The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Should we still use HU first line for PV patients?
Andrew Kuykendall Moffitt Cancer Center, Tampa, FL, United States
Endpoints in MPNs
Should SVR35 still be the gold standard in MF?
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Is there a ceiling in assessing symptom response for MF/ MPN?
Ruben Mesa Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
Future of clinical trials in MF – an industry perspective
David Steensma Ajax Therapeutics, Cambridge, MA, United States
Disease modification as an endpoint in PCV/ET
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
CMML and BPDCN
RASopathies, key features of RAS family-mutated CMML and treatment options
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Approaches from the MDS/MPN IWG – ABNL-MARRO and beyond
Daniel Wiseman The Christie NHS Foundation Trust, Manchester, United Kingdom
The special case of MDS/MPN-RS-T
Valeria Santini University of Florence, Florence, Italy
Updates in BPDCN
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Unmet needs in MF
Updates with combination therapy in MF in first line I – pelabresib
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Updates in frontline combo MF II – BCL-xL – navitoclax & selinexor
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
New options for thrombocytopenia and anemia in MF
Aaron Gerds Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States
Pre-fibrotic MF
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Accelerated disease and transplant
How to define accelerated phase MPN
Lucia Masarova The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Transplantation for MF in chronic and accelerated phase
Donal McLornan University College Hospital, London, United Kingdom
Pathologist features of MPN in evolution
Mina Xu New Haven, CT, United States
Targeting the iron pathway from anemia to polycythemia
Utilizing momelotinib to treat anemia in MPN
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Targeting anemia in MF with luspatercept
Aaron Gerds Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States
Controlling erythrocytosis with rusfertide in PV
Ronald Hoffman Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Clinical experience targeting hepcidin pathways in PV
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Overlaps with MDS
Targeting telomerase in MPN and MDS
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
What MDS/MPN overlap syndromes should be in 2024?
Daniel Wiseman The Christie NHS Foundation Trust, Manchester, United Kingdom
Explore roundtable discussions
View all
Supported by:
